Last 12 months
Inside the activity.
0 purchase rows · 29 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 10 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2021 Filed Jun 29, 2021 21:20 UTC |
Burow KristinaDirector
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006091 · form4.xml · nonDerivative · entry 5 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,121,519 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. The Reporting Person has an interest in the Overage GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jun 29, 2021 21:20 UTC |
Burow KristinaDirector
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006091 · form4.xml · nonDerivative · entry 4 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,121,520 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. The Reporting Person has an interest in the GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH IX. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 22:00 UTC |
Evans John M.Director · Chief Executive Officer
|
OtherCommon Stock | 32 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026781 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,525 F1 · kind: Distribution of BEAM common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 12,045 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · derivative · entry 7 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,175 Underlying: Common Stock · 12,045 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F7 · derivative.exercise_date: The option vests as to one third on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 4.17% each month thereafter until the option is fully vested. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 1,000 | $109.39 | $109,390.00 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · nonDerivative · entry 6 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 900 | $108.30 | $97,470.00 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · nonDerivative · entry 5 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.12 to $108.60, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 1,162 | $107.22 | $124,589.64 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · nonDerivative · entry 4 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.60, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 3,196 | $106.28 | $339,670.88 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · nonDerivative · entry 3 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,062 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.77, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 5,787 | $105.37 | $609,776.19 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · nonDerivative · entry 2 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,258 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.98, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
Exercise / conversionCommon Stock | 12,045 | $17.00 | $204,765.00 |
DisclosureSEC source: 0000899243-21-026782 · doc4.xml · nonDerivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
Evans John M.Director · Chief Executive Officer
|
OtherCommon Stock | 32 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026781 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,493 F1 · kind: Distribution of BEAM common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
Ciaramella GiuseppePresident & CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 78,580 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · derivative · entry 10 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,313 Underlying: Common Stock · 78,580 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F11 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
Ciaramella GiuseppePresident & CSO
|
SaleCommon Stock | 2,173 | $110.00 | $239,030.00 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 9 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,761 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.01, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
Ciaramella GiuseppePresident & CSO
|
SaleCommon Stock | 9,856 | $109.32 | $1,077,457.92 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 8 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,934 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.95, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
Ciaramella GiuseppePresident & CSO
|
SaleCommon Stock | 30,369 | $108.11 | $3,283,192.59 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 7 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,790 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to $108.90, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
Ciaramella GiuseppePresident & CSO
|
SaleCommon Stock | 10,829 | $107.30 | $1,161,951.70 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 6 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,159 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.99, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
Ciaramella GiuseppePresident & CSO
|
SaleCommon Stock | 10,444 | $106.35 | $1,110,719.40 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 5 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,988 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.97, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
Ciaramella GiuseppePresident & CSO
|
SaleCommon Stock | 7,040 | $105.52 | $742,860.80 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 4 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,432 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.01 to $105.98, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
Ciaramella GiuseppePresident & CSO
|
SaleCommon Stock | 5,464 | $104.40 | $570,441.60 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 3 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,472 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.04 to $104.96, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
Ciaramella GiuseppePresident & CSO
|
SaleCommon Stock | 2,405 | $103.83 | $249,711.15 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 2 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,936 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.74 to $103.97, inclusive. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC |
Ciaramella GiuseppePresident & CSO
|
Exercise / conversionCommon Stock | 78,580 | $17.00 | $1,335,860.00 |
DisclosureSEC source: 0000899243-21-026780 · doc4.xml · nonDerivative · entry 1 Ciaramella Giuseppe · CIK 0001786322 · President & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · derivative · entry 9 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,941 Underlying: Common Stock · 45,000 shares Expires 2029-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F10 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
|
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | SaleCommon Stock | 19,800 | $109.41 | $2,166,318.00 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 8 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,809 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.98, inclusive. Read SEC document |
|
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | SaleCommon Stock | 4,803 | $108.45 | $520,885.35 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 7 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,609 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to $108.99, inclusive. Read SEC document |
|
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | SaleCommon Stock | 3,290 | $107.20 | $352,688.00 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 6 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,412 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.90, inclusive. Read SEC document |
|
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | SaleCommon Stock | 8,907 | $106.13 | $945,299.91 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 5 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,702 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.89, inclusive. Read SEC document |
|
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | SaleCommon Stock | 5,220 | $105.34 | $549,874.80 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 4 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,609 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.00 to $105.95, inclusive. Read SEC document |
|
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | SaleCommon Stock | 1,880 | $104.63 | $196,704.40 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 3 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,829 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.58 to $104.96, inclusive. Read SEC document |
|
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | SaleCommon Stock | 1,100 | $103.86 | $114,246.00 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 2 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,709 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.74 to $103.97, inclusive. Read SEC document |
|
| June 28, 2021 Filed Jun 30, 2021 22:00 UTC | Exercise / conversionCommon Stock | 45,000 | $13.68 | $615,600.00 |
DisclosureSEC source: 0000899243-21-026779 · doc4.xml · nonDerivative · entry 1 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
|
| June 25, 2021 Filed Jun 29, 2021 21:22 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 4,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006092 · form4.xml · nonDerivative · entry 5 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,739 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7 · ownership.direct: Shares held directly by Nelsen. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:22 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 811 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006092 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,245 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:22 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 2,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006092 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,218 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:22 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006092 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,321,519 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:22 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006092 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,321,520 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:20 UTC |
Burow KristinaDirector
|
OtherCommon Stock | 2,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006091 · form4.xml · nonDerivative · entry 3 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,045 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:20 UTC |
Burow KristinaDirector
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006091 · form4.xml · nonDerivative · entry 2 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,321,519 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. The Reporting Person has an interest in the Overage GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 21:20 UTC |
Burow KristinaDirector
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006091 · form4.xml · nonDerivative · entry 1 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,321,520 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. The Reporting Person has an interest in the GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH IX. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 22:00 UTC |
Evans John M.Director · Chief Executive Officer
|
OtherCommon Stock | 32 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-026781 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,461 F1 · kind: Distribution of BEAM common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 12:02 UTC |
Fishman MarkDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,877 | $0.00 Strike: $87.91 | $0.00 |
DisclosureSEC source: 0000899243-21-023471 · doc4.xml · derivative · entry 1 Fishman Mark · CIK 0001786003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877 Underlying: Common Stock · 6,877 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 11:57 UTC |
Ho CaroleDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,877 | $0.00 Strike: $87.91 | $0.00 |
DisclosureSEC source: 0000899243-21-023469 · doc4.xml · derivative · entry 1 Ho Carole · CIK 0001724605 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877 Underlying: Common Stock · 6,877 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 11:55 UTC |
Burow KristinaDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,877 | $0.00 Strike: $87.91 | $0.00 |
DisclosureSEC source: 0000899243-21-023467 · doc4.xml · derivative · entry 1 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877 Underlying: Common Stock · 6,877 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 11:53 UTC |
Walsh Kathleen EDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,126 | $0.00 Strike: $87.91 | $0.00 |
DisclosureSEC source: 0000899243-21-023465 · doc4.xml · derivative · entry 1 Walsh Kathleen E · CIK 0001667866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,126 Underlying: Common Stock · 3,126 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 11:52 UTC |
COOPER GRAHAM KDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,877 | $0.00 Strike: $87.91 | $0.00 |
DisclosureSEC source: 0000899243-21-023464 · doc4.xml · derivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877 Underlying: Common Stock · 6,877 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| April 23, 2021 Filed Apr 23, 2021 20:45 UTC |
Evans John M.Director · CEO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · derivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,345 Underlying: Common Stock · 6,000 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| April 23, 2021 Filed Apr 23, 2021 20:45 UTC |
Evans John M.Director · CEO
|
Exercise / conversionCommon Stock | 6,000 | $1.03 | $6,180.00 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:45 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 2,994 | $71.79 | $214,939.26 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,015,429 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: These shares were sold in multiple transactions ranging from $71.68 to $71.92 inclusive. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:45 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 9,869 | $71.38 | $704,449.22 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,018,423 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: These shares were sold in multiple transactions ranging from $70.68 to $71.66 inclusive. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:45 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 5,595 | $70.23 | $392,936.85 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,028,292 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: These shares were sold in multiple transactions ranging from $69.68 to $70.68 inclusive. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:45 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 5,079 | $69.02 | $350,552.58 |
DisclosureSEC source: 0000899243-21-016869 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,033,887 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan. Each price reported for transactions affected pursuant to the Rule 10b5-1 trading plan is a weighted average price. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: These shares were sold in multiple transactions ranging from $68.67 to $69.55 inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.